Cargando…

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

OBJECTIVES: The efficacy and safety of sifalimumab were assessed in a phase IIb, randomised, double-blind, placebo-controlled study (NCT01283139) of adults with moderate to severe active systemic lupus erythematosus (SLE). METHODS: 431 patients were randomised and received monthly intravenous sifali...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khamashta, Munther, Merrill, Joan T, Werth, Victoria P, Furie, Richard, Kalunian, Kenneth, Illei, Gabor G, Drappa, Jorn, Wang, Liangwei, Greth, Warren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099191/ https://www.ncbi.nlm.nih.gov/pubmed/27009916 http://dx.doi.org/10.1136/annrheumdis-2015-208562

Ejemplares similares

Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus
por: Furie, Richard, et al.
Publicado: (2017)

Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus
por: Merrill, Joan T, et al.
Publicado: (2018)

Sifalimumab, a Human Anti–Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study: A Phase I Randomized, Controlled, Dose-Escalation Study
por: Petri, Michelle, et al.
Publicado: (2013)

Population Pharmacokinetics of Sifalimumab, an Investigational Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus
por: Narwal, Rajesh, et al.
Publicado: (2013)

Efficacy of sifalimumab for treatment of skin injury caused by systemic lupus erythematosus
por: Huo, Ai-xin, et al.
Publicado: (2019)

A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients
por: Higgs, Brandon W, et al.
Publicado: (2014)

Structural Insights into the Neutralization Properties of the Fully Human, Anti-interferon Monoclonal Antibody Sifalimumab
por: Oganesyan, Vaheh, et al.
Publicado: (2015)

Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus
por: Yao, Yihong, et al.
Publicado: (2010)

Evaluating duration of response to treatment in systemic lupus erythematosus clinical trials
por: Kim, Mimi, et al.
Publicado: (2018)

A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus
por: Kalunian, Kenneth C., et al.
Publicado: (2022)

Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study
por: Furie, Richard A, et al.
Publicado: (2022)

Subacute cutaneous lupus erythematosus and systemic lupus erythematosus associated with abatacept
por: Tarazi, Meera, et al.
Publicado: (2018)

Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus
por: Buyon, Jill, et al.
Publicado: (2016)

Alopecias in lupus erythematosus
por: Concha, Josef Symon Salgado, et al.
Publicado: (2018)

Interferon Alpha in Systemic Lupus Erythematosus
por: Niewold, Timothy B., et al.
Publicado: (2010)

Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine
por: Reynolds, John A, et al.
Publicado: (2022)

Pathophysiology of cutaneous lupus erythematosus
por: Achtman, Jordan C, et al.
Publicado: (2015)

Monoclonal Antibodies for Systemic Lupus Erythematosus (SLE) †
por: Ponticelli, Claudio, et al.
Publicado: (2010)

Subacute cutaneous lupus erythematosus versus discoid lupus erythematosus: A challenging diagnosis
por: Kleitsch, Julianne, et al.
Publicado: (2023)

British isles lupus assessment group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus
por: Yee, Chee-Seng, et al.
Publicado: (2007)

Improved monitoring of clinical response in Systemic Lupus Erythematosus by longitudinal trend in soluble vascular cell adhesion molecule-1
por: Lewis, Myles J., et al.
Publicado: (2016)

Biological impact of iberdomide in patients with active systemic lupus erythematosus
por: Lipsky, Peter E, et al.
Publicado: (2022)

Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab
por: Morand, Eric F, et al.
Publicado: (2018)

Interferon targeted therapies in systemic lupus erythematosus
por: Misra, Durga Prasanna, et al.
Publicado: (2017)

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus
por: Furie, Richard, et al.
Publicado: (2008)

Suppression of soluble T cell-associated proteins by an anti-interferon-α monoclonal antibody in adult patients with dermatomyositis or polymyositis
por: Guo, Xiang, et al.
Publicado: (2014)

Advancing understanding, diagnosis, and therapies for cutaneous lupus erythematosus within the broader context of systemic lupus erythematosus
por: Chen, Kristen L., et al.
Publicado: (2019)

The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients
por: Yee, Chee-Seng, et al.
Publicado: (2011)

A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus
por: Askanase, Anca D., et al.
Publicado: (2022)

Emerging Therapies in Cutaneous Lupus Erythematosus
por: Sprow, Grant, et al.
Publicado: (2022)

Literature review of lupus nephritis From the Arabian Gulf region
por: Al-Shujairi, Arwa, et al.
Publicado: (2022)

Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood
por: Bennett, Lynda, et al.
Publicado: (2003)

Systemic lupus erythematosus and the type I interferon system
por: Rönnblom, Lars, et al.
Publicado: (2003)

Expanded circulating transitional B cells in a patient with systemic lupus erythematosus
por: Ettinger, R, et al.
Publicado: (2003)

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial
por: Morand, Eric, et al.
Publicado: (2022)

The Role of Genetic Variation Near Interferon-Kappa in Systemic Lupus Erythematosus
por: Harley, Isaac T. W., et al.
Publicado: (2010)

Bullous systemic lupus erythematosus in females
por: Sprow, Grant, et al.
Publicado: (2022)

The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis
por: Kivitz, Alan, et al.
Publicado: (2023)

Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study
por: Hanly, John G., et al.
Publicado: (2019)

Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus
por: Furie, Richard A, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h3b6tcdjq39mlsgu9nej6u9rfe